Literature DB >> 23071332

Induced pluripotent stem cell model recapitulates pathologic hallmarks of Gaucher disease.

Leelamma M Panicker1, Diana Miller, Tea Soon Park, Brijesh Patel, Judi L Azevedo, Ola Awad, M Athar Masood, Timothy D Veenstra, Ehud Goldin, Barbara K Stubblefield, Nahid Tayebi, Swamy K Polumuri, Stefanie N Vogel, Ellen Sidransky, Elias T Zambidis, Ricardo A Feldman.   

Abstract

Gaucher disease (GD) is an autosomal recessive disorder caused by mutations in the acid β-glucocerebrosidase gene. To model GD, we generated human induced pluripotent stem cells (hiPSC), by reprogramming skin fibroblasts from patients with type 1 (N370S/N370S), type 2 (L444P/RecNciI), and type 3 (L444P/L444P) GD. Pluripotency was demonstrated by the ability of GD hiPSC to differentiate to all three germ layers and to form teratomas in vivo. GD hiPSC differentiated efficiently to the cell types most affected in GD, i.e., macrophages and neuronal cells. GD hiPSC-macrophages expressed macrophage-specific markers, were phagocytic, and were capable of releasing inflammatory mediators in response to LPS. Moreover, GD hiPSC-macrophages recapitulated the phenotypic hallmarks of the disease. They exhibited low glucocerebrosidase (GC) enzymatic activity and accumulated sphingolipids, and their lysosomal functions were severely compromised. GD hiPSC-macrophages had a defect in their ability to clear phagocytosed RBC, a phenotype of tissue-infiltrating GD macrophages. The kinetics of RBC clearance by types 1, 2, and 3 GD hiPSC-macrophages correlated with the severity of the mutations. Incubation with recombinant GC completely reversed the delay in RBC clearance from all three types of GD hiPSC-macrophages, indicating that their functional defects were indeed caused by GC deficiency. However, treatment of induced macrophages with the chaperone isofagomine restored phagocytosed RBC clearance only partially, regardless of genotype. These findings are consistent with the known clinical efficacies of recombinant GC and isofagomine. We conclude that cell types derived from GD hiPSC can effectively recapitulate pathologic hallmarks of the disease.

Entities:  

Mesh:

Year:  2012        PMID: 23071332      PMCID: PMC3497826          DOI: 10.1073/pnas.1207889109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  Impaired autophagosomes and lysosomes in neuronopathic Gaucher disease.

Authors:  Ying Sun; Gregory A Grabowski
Journal:  Autophagy       Date:  2010-07-01       Impact factor: 16.016

2.  An ultrastructural and experimental study on the development of tubular structures in the lysosomes of Gaucher cells.

Authors:  M Naito; K Takahashi; H Hojo
Journal:  Lab Invest       Date:  1988-05       Impact factor: 5.662

Review 3.  Gaucher disease: pathological mechanisms and modern management.

Authors:  Marina Jmoudiak; Anthony H Futerman
Journal:  Br J Haematol       Date:  2005-04       Impact factor: 6.998

4.  A histochemical and electron microscopic study of Gaucher cells.

Authors:  R G Hibbs; V J Ferrans; P R Cipriano; K J Tardiff
Journal:  Arch Pathol       Date:  1970-02

5.  Divergent phenotypes in Gaucher disease implicate the role of modifiers.

Authors:  O Goker-Alpan; K S Hruska; E Orvisky; P S Kishnani; B K Stubblefield; R Schiffmann; E Sidransky
Journal:  J Med Genet       Date:  2005-06       Impact factor: 6.318

6.  Gaucher's disease. A morphologic study and measurements of iron metabolism.

Authors:  R E Lee; S P Balcerzak; M P Westerman
Journal:  Am J Med       Date:  1967-06       Impact factor: 4.965

7.  Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors.

Authors:  Kazutoshi Takahashi; Shinya Yamanaka
Journal:  Cell       Date:  2006-08-10       Impact factor: 41.582

Review 8.  Enzyme replacement for lysosomal diseases.

Authors:  Roscoe O Brady
Journal:  Annu Rev Med       Date:  2006       Impact factor: 13.739

9.  Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype.

Authors:  Eduard Orvisky; Joseph K Park; Mary E LaMarca; Edward I Ginns; Brian M Martin; Nahid Tayebi; Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2002-08       Impact factor: 4.797

Review 10.  Gaucher disease: complexity in a "simple" disorder.

Authors:  Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2004 Sep-Oct       Impact factor: 4.797

View more
  59 in total

1.  [Leukocyte count of puerperal sows].

Authors:  D Mäde; G Wujanz
Journal:  Berl Munch Tierarztl Wochenschr       Date:  1996-09       Impact factor: 0.328

Review 2.  Advancing Biological Understanding and Therapeutics Discovery with Small-Molecule Probes.

Authors:  Stuart L Schreiber; Joanne D Kotz; Min Li; Jeffrey Aubé; Christopher P Austin; John C Reed; Hugh Rosen; E Lucile White; Larry A Sklar; Craig W Lindsley; Benjamin R Alexander; Joshua A Bittker; Paul A Clemons; Andrea de Souza; Michael A Foley; Michelle Palmer; Alykhan F Shamji; Mathias J Wawer; Owen McManus; Meng Wu; Beiyan Zou; Haibo Yu; Jennifer E Golden; Frank J Schoenen; Anton Simeonov; Ajit Jadhav; Michael R Jackson; Anthony B Pinkerton; Thomas D Y Chung; Patrick R Griffin; Benjamin F Cravatt; Peter S Hodder; William R Roush; Edward Roberts; Dong-Hoon Chung; Colleen B Jonsson; James W Noah; William E Severson; Subramaniam Ananthan; Bruce Edwards; Tudor I Oprea; P Jeffrey Conn; Corey R Hopkins; Michael R Wood; Shaun R Stauffer; Kyle A Emmitte
Journal:  Cell       Date:  2015-06-04       Impact factor: 41.582

3.  Gaucher Disease-Induced Pluripotent Stem Cells Display Decreased Erythroid Potential and Aberrant Myelopoiesis.

Authors:  Judi A Sgambato; Tea Soon Park; Diana Miller; Leelamma M Panicker; Ellen Sidransky; Yu Lun; Ola Awad; Søren M Bentzen; Elias T Zambidis; Ricardo A Feldman
Journal:  Stem Cells Transl Med       Date:  2015-06-10       Impact factor: 6.940

4.  Niemann-Pick Disease Type C: Induced Pluripotent Stem Cell-Derived Neuronal Cells for Modeling Neural Disease and Evaluating Drug Efficacy.

Authors:  Daozhan Yu; Manju Swaroop; Mengqiao Wang; Ulrich Baxa; Rongze Yang; Yiping Yan; Turhan Coksaygan; Louis DeTolla; Juan J Marugan; Christopher P Austin; John C McKew; Da-Wei Gong; Wei Zheng
Journal:  J Biomol Screen       Date:  2014-06-06

5.  Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs.

Authors:  Elma Aflaki; Barbara K Stubblefield; Emerson Maniwang; Grisel Lopez; Nima Moaven; Ehud Goldin; Juan Marugan; Samarjit Patnaik; Amalia Dutra; Noel Southall; Wei Zheng; Nahid Tayebi; Ellen Sidransky
Journal:  Sci Transl Med       Date:  2014-06-11       Impact factor: 17.956

Review 6.  Lysosomal storage diseases.

Authors:  Frances M Platt; Alessandra d'Azzo; Beverly L Davidson; Elizabeth F Neufeld; Cynthia J Tifft
Journal:  Nat Rev Dis Primers       Date:  2018-10-01       Impact factor: 52.329

Review 7.  Glycosylation and stem cells: Regulatory roles and application of iPSCs in the study of glycosylation-related disorders.

Authors:  Ryan P Berger; Michelle Dookwah; Richard Steet; Stephen Dalton
Journal:  Bioessays       Date:  2016-09-26       Impact factor: 4.345

8.  Gaucher iPSC-derived macrophages produce elevated levels of inflammatory mediators and serve as a new platform for therapeutic development.

Authors:  Leelamma M Panicker; Diana Miller; Ola Awad; Vivek Bose; Yu Lun; Tea Soon Park; Elias T Zambidis; Judi A Sgambato; Ricardo A Feldman
Journal:  Stem Cells       Date:  2014-09       Impact factor: 6.277

Review 9.  Modelling human disease with pluripotent stem cells.

Authors:  Richard Siller; Sebastian Greenhough; In-Hyun Park; Gareth J Sullivan
Journal:  Curr Gene Ther       Date:  2013-04       Impact factor: 4.391

Review 10.  Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease.

Authors:  Olive Jung; Samarjit Patnaik; Juan Marugan; Ellen Sidransky; Wendy Westbroek
Journal:  Expert Rev Proteomics       Date:  2016-04-21       Impact factor: 3.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.